11 recruiting, 10 active not recruiting, 3 completed, 2 not yet recruiting. 28 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 28 | Recruiting 11, Active not recruiting 10, Completed 3, Not yet recruiting 2, Terminated 2 |
| Phase 1 | 8 | Active not recruiting 4, Recruiting 3, Completed 1 |
Follow amivantamab: new trials by email Literature Review of amivantamab trials Research Report on amivantamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma Amivantamab - Penile Squamous Cell Carcinoma, Metastatic Penile Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Latin American Cooperative Oncology Group | 58 | 2026-11-01 | 2026-09-14 |
| A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC Amivantamab, Lazertinib, Carboplatin - Carcinoma, Non-Small-Cell Lung | Phase 2 | Recruiting | Janssen Research & Development, LLC | 68 | 2026-07-28 | 2026-09-25 |
| Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System Amivantamab and Recombinant Human Hyaluronidase, Biospecimen Collection, Cetuximab - Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-03-23 | 2026-10-15 |
| A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer Amivantamab, Olomorasib - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Recruiting | Janssen Research & Development, LLC | 60 | 2026-03-03 | 2026-09-25 |
| Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations. Amivantamab - Metastatic NSCLC - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Fondazione Ricerca Traslazionale | 33 | 2025-12-02 | 2026-02-06 |
| An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment. Amivantamab + FOLFIRI - RAS/BRAF Wild-type Advanced Colorectal Cancer Patients | Phase 2 | Not yet recruiting | Yonsei University | 85 | 2025-05-01 | 2025-03-04 |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Amivantamab, Lazertinib, Chemotherapy: Pemetrexed - Carcinoma, Non-Small-Cell Lung | Phase 2 | Recruiting | Janssen Research & Development, LLC | 480 | 2024-12-16 | 2026-09-25 |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) Amivantamab, Biospecimen Collection, Computed Tomography - Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 88 | 2024-11-19 | 2026-10-09 |
| A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer Amivantamab, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Completed | Janssen Research & Development, LLC | 12 | 2024-07-23 | 2026-07-31 |
| PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer Amivantamab, Tepotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2024-06-18 | 2026-09-11 |
| A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer Amivantamab, Pembrolizumab, Paclitaxel - Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Recruiting | Janssen Research & Development, LLC | 287 | 2024-04-22 | 2026-09-25 |
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib Amivantamab IV, Amivantamab SC, Lazertinib - Carcinoma, Non-Small-Cell Lung | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 305 | 2024-02-16 | 2026-09-25 |
| A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations Osimertinib, Amivantamab - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Active not recruiting | AstraZeneca | 60 | 2023-07-18 | 2026-09-08 |
| Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined) - Lung Cancer, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | University of Colorado, Denver | 12 | 2023-07-17 | 2026-09-29 |
| Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations Amivantamab, Lazertinib, Pemetrexed 500 mg - Metastatic Non-small Cell Lung Cancers | Phase 2 | Completed | Latin American Cooperative Oncology Group | 54 | 2023-05-24 | 2026-08-28 |
| A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer Cetrelimab, Amivantamab - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 71 | 2023-05-18 | 2026-09-25 |
| Premedication to Reduce Amivantamab Associated Infusion Related Reactions Dexamethasone, Montelukast, Methotrexate - Carcinoma, Non-Small-Cell Lung | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 68 | 2023-05-18 | 2026-09-25 |
| Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) Trastuzumab deruxtecan, Durvalumab, Panitumumab - Colorectal Cancer, Resectable Colorectal Carcinoma | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 197 | 2023-05-11 | 2026-09-11 |
| Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI Amivantamab, Lazertinib, Zirabev - Non Small Cell Lung Cancer | Phase 2 | Active not recruiting | ETOP IBCSG Partners Foundation | 60 | 2023-03-27 | 2026-01-21 |
| A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer Capmatinib, Amivantamab - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 57 | 2022-12-13 | 2026-09-25 |
Showing 20 of 28. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (16) · Colorectal Neoplasms (2) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Hepatocellular (1) · Esophageal Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Salivary Gland Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
Janssen Research & Development, LLC (12) · Latin American Cooperative Oncology Group (2) · Memorial Sloan Kettering Cancer Center (2) · AstraZeneca (1) · ETOP IBCSG Partners Foundation (1) · Fondazione Ricerca Traslazionale (1) · Gruppo Oncologico del Nord-Ovest (1) · Janssen Pharmaceutical K.K. (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · SWOG Cancer Research Network (1) · Trisha Wise-Draper (1) · University of Colorado, Denver (1) · Vall d'Hebron Institute of Oncology (1) · Yonsei University (1)
United States (18) · South Korea (11) · Spain (11) · Italy (9) · China (8) · France (8) · United Kingdom (8) · Germany (7) · Taiwan (7) · Brazil (6) · Malaysia (6) · Turkey (Türkiye) (5) · Canada (4) · Japan (4) · Poland (4)
Erin Schenk, MD, PhD (1) · Fernando Cotait Maluf (1) · Fernando Sabino (1) · Filippo Pietrantonio, MD (1) · Helena Yu, MD (1) · Jordi Rodon, MD (1) · Paul L Swiecicki (1) · Ross Soo, MD FRACP (1) · Shirish Gadgeel (1) · Steven Maron, MD (1) · Trisha Wise-Draper, MD, PhD (1)
PMID 39864547, PMID 40923969, PMID 41139066, PMID 41746627, PMID 42013403, PMID 42218660, PMID 42833236
2023 (6), U10CA180888 (2), 2017 (1), 2025 (1)